Axxcess Wealth Management LLC Buys 1,594 Shares of Edwards Lifesciences Co. (NYSE:EW)

Axxcess Wealth Management LLC grew its stake in Edwards Lifesciences Co. (NYSE:EW) by 8.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,839 shares of the medical research company’s stock after acquiring an additional 1,594 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Edwards Lifesciences were worth $1,896,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Delap Wealth Advisory LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $305,000. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $28,000. Tiemann Investment Advisors LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth $222,000. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Edwards Lifesciences by 21,094.6% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 19,711 shares of the medical research company’s stock worth $1,884,000 after purchasing an additional 19,618 shares during the last quarter. Finally, Saturna Capital Corp raised its stake in shares of Edwards Lifesciences by 5.2% in the first quarter. Saturna Capital Corp now owns 22,611 shares of the medical research company’s stock worth $2,161,000 after purchasing an additional 1,109 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total value of $466,450.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $4,378,659.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of Edwards Lifesciences stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the transaction, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. In the last three months, insiders sold 81,099 shares of company stock valued at $7,003,553. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $2.67 during mid-day trading on Friday, reaching $62.37. The company had a trading volume of 14,111,391 shares, compared to its average volume of 5,310,790. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.71 and a quick ratio of 2.67. The company has a market capitalization of $37.58 billion, a P/E ratio of 26.88, a P/E/G ratio of 2.22 and a beta of 1.11. The stock’s 50-day simple moving average is $87.98 and its 200-day simple moving average is $86.84.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The company had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the company posted $0.66 earnings per share. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. On average, equities analysts predict that Edwards Lifesciences Co. will post 2.73 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the subject of a number of research reports. Evercore ISI reduced their price objective on Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating for the company in a research report on Thursday. Stifel Nicolaus reduced their price objective on Edwards Lifesciences from $85.00 to $70.00 and set a “hold” rating for the company in a research report on Thursday. Oppenheimer reduced their price objective on Edwards Lifesciences from $100.00 to $90.00 and set an “outperform” rating for the company in a research report on Thursday. Barclays reduced their price objective on Edwards Lifesciences from $101.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday. Finally, Canaccord Genuity Group reduced their price objective on Edwards Lifesciences from $85.00 to $77.00 and set a “hold” rating for the company in a research report on Thursday. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Hold” and an average target price of $82.10.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.